Exam 6 - (CH 26) Mycobacterium tuberculosis and Nontuberculous Mycobacteria Textbook Review Questions Flashcards
If sputum or bronchial washings are cultured during the primary tuberculosis infection, the positivity rate is
A. 15% to 20%.
B. 25% to 30%.
C. 45% to 55%.
D. 70% to 80%.
B. 25% to 30%.
Skeletal tuberculosis of the spine is
A. scurvy.
B. Hansen disease.
C. Pott disease.
D. Whipple’s disease.
C. Pott disease.
Which of the following colony description best describes Mycobacterium bovis?
A. Pinpoint, smooth, concave, and buff-colored
B. Larger, irregular, flat, and translucent
C. Small, irregular, rounded with yellow-orange pigment
D. Small, granular, rounded, and nonpigmented
D. Small, granular, rounded, and nonpigmented
Long, thin, beaded bacilli resembling Nocardia spp. may be seen in the young cultures of
A. Mycobacterium intracellulare.
B. Mycobacterium tuberculosis.
C. Mycobacterium bovis.
D. Mycobacterium kansasii.
A. Mycobacterium intracellulare.
Cervical lymphadenitis in children is most associated with
A. Mycobacterium marinum.
B. Mycobacterium ulcerans.
C. Mycobacterium kansasii.
D. Mycobacterium scrofulaceum.
D. Mycobacterium scrofulaceum.
Mycobacterium ulcerans grows best under these conditions:
A. 28°C to 30°C
B. Microaerophilic at 37°C
C. Capnophilic at 25°C
D. 37°C to 42°C
A. 28°C to 30°C
Which set of reactions is consistent with Mycobacterium chelonae?
A. Arylsulfatase and sodium citrate negative
B. Arylsulfatase and mannitol positive
C. Arylsulfatase positive and nitrate reduction negative
D. Arylsulfatase negative and inositol positive
C. Arylsulfatase positive and nitrate reduction negative
The current therapy recommended for lepromatous leprosy consists of
A. diaminodiphenylsulfone and rifampin for 6 months.
B. clofazimine for 12 months.
C. quinolones of 3 months.
D. triple therapy of a azithromycin, tetracycline, and bismuth salt for 12 months.
A. diaminodiphenylsulfone and rifampin for 6 months.
This is a liquid broth used for subculturing stock strains and preparing inoculum for in vitro testing of Mycobacterium spp.
A. MGIT
B. Middlebrook 7H11
C. Middlebrook 7H9
D. Mycobactosel
Middlebrook 7H9
Some bacteria are able to hydrolyze Tween 80 into
A. pyrazinamide and ammonia.
B. ferric ammonium citrate and iron oxide.
C. cyanogen bromide and NaOH.
D. oleic acid and polyoxyethylated sorbitol.
D. oleic acid and polyoxyethylated sorbitol.
Which species is able to grow in the presence of high salt concentration in egg-based media?
A. Mycobacterium tuberculosis
B. Mycobacterium scrofulaceum
C. Mycobacterium szulgai
D. Mycobacterium flavescens
D. Mycobacterium flavescens
Which statement is true regarding the Quantiferon-TB Gold assay?
A. It is an interferon-alpha inhibition assay.
B. It detects a patients’ cell-mediated immune response to the bacterial antigens in a type IV hypersensitivity reaction.
C. It will be positive if the patient has been vaccinated with the BCG vaccination.
D. It is not affected by the BCG vaccination.
D. It is not affected by the BCG vaccination.
Describe the current recommendations for the identification of M. tuberculosis in the clinical laboratory.
Many mycobacterial species, saprophytes and potential pathogens, may be isolated from humans. Historically, mycobacteria have been identified by growth characteristics and biochemical testing. More recently, molecular biology assays have been developed. These assays include mycolic acid analysis of bacterial cell walls by high-pressure liquid chromatography, DNA probe technology, DNA sequencing, and MALDI-TOF MS. Genetic probe technology offers tremendous promise in microbial identification at a variety of levels— family, genus, species, and subspecies. The most common probe technology is the commercially available, single-stranded, acridinium ester– labeled DNA probe for the detection of rRNA (Gen-Probe, San Diego, CA). Probes specific for the M. tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. canettii, and M. microti), M. kansasii, and M. gordonae, and separate probes for M. avium and M. intracellulare, are available. Laboratories should perform identification according to the level of service for which they are qualified. All isolates should be identified to the species level.
Explain why mycobacterial infections should be treated for 6 months or longer and the need to use multiple drugs when treating M. tuberculosis infections.
Slowly growing M. tuberculosis has the extraordinary ability to persist and replicate in the harsh environment of the alveolar macrophage. The pathogenic mycobacteria are slow growers, which also lends to drug resistance. Antimicrobial agents are more active against rapidly growing bacteria. The American Thoracic Society, Centers for Disease Control and Prevention, and the International Union Against Tuberculosis and Lung Disease recommend a regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for the first 8 weeks, for the treatment of tuberculosis. This is followed by isoniazid and rifampin for 18 weeks. Multidrug-resistant tuberculosis, defined as an isolate resistant to at least isoniazid and rifampin, is more complicated to treat.
Compare the different levels of mycobacterial laboratory testing, and explain why smaller-volume laboratories should consider not performing full identification and susceptibility testing on mycobacterial isolates.
Mycobacteriologic services are available in many laboratories. Clinical laboratory functions that contribute to the diagnosis and management of tuberculosis have been divided into the following three major categories of service offered. * Level 1: Collection and transport of specimens, preparation and examination of smears for acid-fast bacilli. * Level 2: Procedures of level 1, plus isolation and identification of M. tuberculosis. * Level 3: All procedures of level 2, plus identification of mycobacteria other than M. tuberculosis.
The determination of drug susceptibility may be performed at level 2 and should be performed at level 3. However, antimicrobial susceptibility testing of the mycobacteria is difficult and should be attempted only by laboratories with experience in this assay. A laboratory may choose to develop or maintain the skills defined under one of the above levels, depending on the frequency with which specimens are received for isolation of mycobacteria, the nature of the clinical community being served, and the availability of a specialized referral service. All laboratories that perform clinical mycobacteriology should participate in recognized proficiency testing programs, and levels of service should be established and limited by the quality of performance demonstrated in these examinations.